FPT155 shows antitumor activity, T cell activation
SOUTH SAN FRANCISCO, Calif.—Five Prime Therapeutics Inc. presented at the recent 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, sharing new preclinical data that demonstrate the potent antitumor activity of FPT155, its novel therapeutic CD80-Fc fusion protein. FPT155 was designed as a co-stimulatory molecule meant to stimulate T cell activation and break tumor immune tolerance. In in-vitro studies, the compound has induced T cell activation and cytokine production via CD28.
“The work done in preclinical models with FPT155 suggests that it has the potential to be a potent T cell co-stimulator with strong antitumor activity, and it may have a synergistic effect when combined with anti-PD1 therapy,” commented Dr. Bryan Irving, senior vice president of research at Five Prime. “These results are very encouraging, and we are working to complete IND-enabling studies in anticipation of an IND filing for FPT155 in mid-2018.”